France Atherosclerosis Therapeutics Market Report 2022 to 2030

France Atherosclerosis Therapeutics Market Executive Summary

France Atherosclerosis Therapeutics Market was valued at $77 Mn in 2022 and is estimated to reach $111 Mn in 2030, exhibiting a CAGR of 4.7% during the forecast period.

Atherosclerosis is a condition characterized by the buildup of plaque, which is a sticky substance made of cholesterol, fat, calcium, and other materials, inside the walls of arteries. This buildup can lead to the narrowing or obstruction of blood vessels, reducing blood flow and increasing the risk of serious conditions such as heart attacks and strokes. The development of atherosclerosis is influenced by various factors, including high blood pressure, elevated cholesterol levels, diabetes, obesity, smoking, a family history of heart disease, physical inactivity, and an unhealthy diet. Several drugs have demonstrated effectiveness in reducing or preventing the progression of atherosclerosis, including beta-blockers, aspirin, and statins.

In France, atherosclerosis is a major public health concern as it significantly increases the burden of cardiovascular disease (CVD). Approximately 30% of adult French people have at least one significant risk factor for atherosclerosis, such as diabetes, obesity, or high cholesterol. Cardiovascular disease (CVD) is the major cause of death in the nation, accounting for approximately one-third of all fatalities. Atherosclerosis-related disorders such as stroke and coronary artery disease are major contributors to CVD. The prevalence of atherosclerosis in France is influenced by several factors. A higher risk of chronic illnesses, such as atherosclerosis, is linked to the aging population. Atherosclerosis risk is further increased by sedentary lifestyles and poor eating patterns that emphasize processed foods and saturated fats. Atherosclerosis can also be predisposed more profoundly by certain genetic variables, with certain societies predisposed to the condition because of their genetic makeup. Moreover, a higher frequency of atherosclerosis in particular groups may be attributed to unequal access to healthcare and a lack of opportunities for healthy living.

Bentavymab, an anti-PCSK9 antibody, is being tested in Phase 3 PRIMO-2 research, which is being carried out by Sanofi and Regeneron to determine if it can lower cardiovascular events in high-risk atherosclerotic patients. Vericept (cilostazol) is being examined by Bayer to determine its safety and efficacy in preventing repeated major adverse cardiovascular events in patients with peripheral artery disease and atherosclerosis. This trial is currently in its Phase 3b stage. The findings have significant potential to improve the quality of care for patients with atherosclerosis and to affect the direction of cardiovascular therapeutics in the future.

Market Dynamics

Market Growth Drivers

Aging Population: The need for treatments related to atherosclerosis is increasing as an aging population makes older people more vulnerable to atherosclerosis. By 2050, 32 million individuals in France are predicted to be elderly, making up around 33% of the nation's overall population. The need to address the therapeutic demands of atherosclerosis is growing because the ailment is more prevalent in the senior population.

High Prevalence: Cardiovascular disease (CVD), the leading cause of death in France, is largely caused by atherosclerosis. With approximately 30% of French adults exhibiting at least one important risk factor for atherosclerosis, there is a high demand in the market for both preventive measures and therapeutic medications to address this prevalent health concern.

Evolving Treatment Landscape: Innovations in technology and pharmaceuticals are propelling the development of new therapeutics, like gene therapies and PCSK9 inhibitors, which will lead to a wider range of highly efficient drugs. This continuous improvement not only expands the options for therapeutics but also increases the market's growth potential. A paradigm shift can be seen in the growing emphasis on personalized medicine, which places more emphasis on tailoring care to a patient's unique genetic profile and risk factors. This strategy is a major step toward improving healthcare outcomes since it guarantees optimal efficacy and expands the pool of people who may benefit from customized drugs.

Market Restraints

Lack of Awareness: A lack of knowledge regarding atherosclerosis and its preventive strategies may make it difficult to intervene early and discourage people from getting treatment promptly. A lack of awareness of atherosclerosis and its preventative techniques might make it difficult for people to identify signs or take timely action to avoid it, which can delay the need for medical intervention and impede market expansion.

Regulatory Hurdles: Prolonged clinical studies and stringent regulatory procedures may present challenges and higher expenses for pharmaceutical companies, delaying the release of new medications. Regulations that are unclear lead to ambiguity, which makes it difficult for firms to operate successfully and plan for approval processes. The unclear regulatory landscape makes it difficult for innovators to estimate requirements and review schedules, which could lead to major delays in the discovery of novel drugs. Because of this intricacy, careful planning and coordination are required at many different phases, such as clinical studies, manufacturing, and marketing approval. The unpredictability of regulations prevents business expansion.

High Drug Cost: The high expense of the drugs used to treat atherosclerosis is a significant barrier for many people, especially those with lower incomes or less access to healthcare. High costs for prescription drugs are a barrier since they limit market penetration and impede overall growth.

Healthcare Policies and Regulatory Landscape

The French National Agency for Medicines and Health Products Safety (Agence Nationale de sécurité du médicament et des produits de santé, or ANSM) and a variety of regulations form the comprehensive framework that governs healthcare policies and regulatory authority for treatment drugs in France. To guarantee the effectiveness, safety, and quality of pharmaceuticals, the ANSM is essential. It assesses requests for marketing authorization, keeps track of medication safety throughout its life, and creates standards for appropriate manufacturing procedures. To comply with European standards and meet particular national criteria, the agency works in conjunction with the European Medicines Agency (EMA). The Health Insurance System (Sécurité Sociale) in France oversees the payment of prescription medications. The Haute Autorité de Santé, also known as the High Health Authority, evaluates pharmaceuticals' medicinal value before recommending them for inclusion in the list of goods that can be reimbursed. This procedure entails assessing the cost-effectiveness, clinical efficacy, and therapeutic value of drugs.

Competitive Landscape

Key Players

• Sanofi
• Novartis
• Pfizer
• Bayer
• AstraZeneca
• Merck Sharp & Dohme
• AbbVie
• Roche
• Johnson & Johnson
• Bristol-Myers Squibb